JP2014515600A5 - - Google Patents

Info

Publication number

JP2014515600A5

JP2014515600A5 JP2014501372A JP2014501372A JP2014515600A5 JP 2014515600 A5 JP2014515600 A5 JP 2014515600A5 JP 2014501372 A JP2014501372 A JP 2014501372A JP 2014501372 A JP2014501372 A JP 2014501372A JP 2014515600 A5 JP2014515600 A5 JP 2014515600A5

Authority

JP

Japan

Prior art keywords

seq

cancer

antibody

antigen

binding fragment

Prior art date

2012-03-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims description 39
• 102000036639 antigens Human genes 0.000 claims description 39
• 108091007433 antigens Proteins 0.000 claims description 39
• 239000012634 fragment Substances 0.000 claims description 37
• 102100040442 Kidney-associated antigen 1 Human genes 0.000 claims description 27
• 206010028980 Neoplasm Diseases 0.000 claims description 15
• 201000011510 cancer Diseases 0.000 claims description 14
• 150000001413 amino acids Chemical class 0.000 claims description 3
• 230000001225 therapeutic effect Effects 0.000 claims description 3
• 239000003814 drug Substances 0.000 claims description 2
• 101710197393 Kidney-associated antigen 1 Proteins 0.000 claims 23
• 239000000203 mixture Substances 0.000 claims 11
• 239000008194 pharmaceutical composition Substances 0.000 claims 11
• 206010033128 Ovarian cancer Diseases 0.000 claims 9
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 9
• 238000000034 method Methods 0.000 claims 8
• 150000007523 nucleic acids Chemical class 0.000 claims 5
• 102000039446 nucleic acids Human genes 0.000 claims 5
• 108020004707 nucleic acids Proteins 0.000 claims 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
• 206010005003 Bladder cancer Diseases 0.000 claims 3
• 208000003174 Brain Neoplasms Diseases 0.000 claims 3
• 206010006187 Breast cancer Diseases 0.000 claims 3
• 208000026310 Breast neoplasm Diseases 0.000 claims 3
• 206010009944 Colon cancer Diseases 0.000 claims 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
• 206010060862 Prostate cancer Diseases 0.000 claims 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
• 206010038389 Renal cancer Diseases 0.000 claims 3
• 206010039491 Sarcoma Diseases 0.000 claims 3
• 208000000453 Skin Neoplasms Diseases 0.000 claims 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
• 201000004101 esophageal cancer Diseases 0.000 claims 3
• 201000010536 head and neck cancer Diseases 0.000 claims 3
• 208000014829 head and neck neoplasm Diseases 0.000 claims 3
• 201000010982 kidney cancer Diseases 0.000 claims 3
• 208000032839 leukemia Diseases 0.000 claims 3
• 201000005202 lung cancer Diseases 0.000 claims 3
• 208000020816 lung neoplasm Diseases 0.000 claims 3
• 201000000849 skin cancer Diseases 0.000 claims 3
• 238000012360 testing method Methods 0.000 claims 3
• 201000002510 thyroid cancer Diseases 0.000 claims 3
• 238000011282 treatment Methods 0.000 claims 3
• 201000005112 urinary bladder cancer Diseases 0.000 claims 3
• 239000013598 vector Substances 0.000 claims 3
• 125000003275 alpha amino acid group Chemical group 0.000 claims 2
• 108010044540 auristatin Proteins 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 239000002254 cytotoxic agent Substances 0.000 claims 2
• 231100000599 cytotoxic agent Toxicity 0.000 claims 2
• 238000001514 detection method Methods 0.000 claims 2
• 238000003745 diagnosis Methods 0.000 claims 2
• 230000001394 metastastic effect Effects 0.000 claims 2
• 206010061289 metastatic neoplasm Diseases 0.000 claims 2
• 230000000306 recurrent effect Effects 0.000 claims 2
• MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
• 101710145634 Antigen 1 Proteins 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
• 239000000611 antibody drug conjugate Substances 0.000 claims 1
• 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 238000004113 cell culture Methods 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000013604 expression vector Substances 0.000 claims 1
• 238000003306 harvesting Methods 0.000 claims 1
• 210000003734 kidney Anatomy 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 208000037819 metastatic cancer Diseases 0.000 claims 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
• 108010093470 monomethyl auristatin E Proteins 0.000 claims 1
• 108010059074 monomethylauristatin F Proteins 0.000 claims 1
• 230000003248 secreting effect Effects 0.000 claims 1
• 210000002966 serum Anatomy 0.000 claims 1
• 239000006228 supernatant Substances 0.000 claims 1
• 210000001519 tissue Anatomy 0.000 claims 1
• 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1